Okamura, Akihiko
Watanabe, Masayuki
Okui, Jun
Matsuda, Satoru
Takemura, Ryo
Kawakubo, Hirofumi
Takeuchi, Hiroya
Muto, Manabu
Kakeji, Yoshihiro
Kitagawa, Yuko
Doki, Yuichiro
Article History
Received: 11 January 2023
Accepted: 11 April 2023
First Online: 1 June 2023
Disclosure
: Yuko Kitagawa has undertaken relevant financial activities outside the submitted work for Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Yakult Honsha Co. Ltd, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Tsumura & Co., Kyouwa Hakkou Kirin Co., Ltd, EA Pharma Co., Ltd, Medicon Inc., Kaken Pharmaceutical Co. Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Factory Inc., Teijin Pharma Limited, Nihon Pharmaceutical Co., Ltd, Nippon Covidien Inc., Shionogi & Co., Ltd, Ethicon, Inc., Olympus Corporation, Bristol-Myers Squibb K.K., AstraZeneca K.K., MSD K.K., Smith & Nephew KK, Aska Pharmaceutical Co., Ltd, Miyarisan Pharmaceutical Co. Ltd. Akihiko Okamura, Masayuki Watanabe, Jun Okui, Satoru Matsuda, Ryo Takemura, Hirofumi Kawakubo, Hiroya Takeuchi, Manabu Muto, Yoshihiro Kakeji, and Yuichiro Doki have no conflicts of interest to declare.